Affini-T Therapeutics Company Research Report
Company Overview
Name:
Affini-T Therapeutics
Mission:
We orchestrate the immune system to target oncogenic driver mutations to deliver transformative therapies intended to cure patients.
Founded:
No information is available.
Founders:
Phil Greenberg, MD; Aude Chapuis, MD; Tom Schmitt, PhD; Christopher A. Klebanoff, MD; Jim Allison, PhD; Padmanee Sharma, MD, PhD; Rafi Ahmed, PhD; David Kranz, PhD; Susan Kaech, PhD.
Key People:
- Jak Knowles, MD - Chief Executive Officer
- Dirk Nagorsen, MD - Chief Medical Officer
- Kathy Bergsteinsson, MBA - Chief Financial Officer
- Kim Nguyen, PhD - Chief Technical Officer
- Loïc Vincent, PhD - Chief Scientific Officer
- Kathy Yi, MBA - Chief Operating Officer
Headquarters:
100 Forge Road, Watertown, MA 02472, Boston
Number of Employees:
No information is available.
Revenue:
No information is available.
Known For:
Affini-T Therapeutics is known for developing TCR-based immunotherapies for solid tumors utilizing innovative T cell therapy-enabling platforms, bispecific T Cell Engagers, and leveraging synthetic biology and gene editing technologies.
Products
Types of Products:
- Autologous TCR-T Cell Therapies
- Bispecific T Cell Engagers
High-Level Description of Products:
Affini-T Therapeutics' products focus on leveraging T cell receptor (TCR)-based immunotherapies targeting oncogenic driver mutations in solid tumors. These products deliver transformative therapies by redirecting and enhancing the body's immune response against cancer cells expressing specific oncogenic driver mutations.
Key Features of Each Product:
Autologous TCR-T Cell Therapies:
1. TAILOR™ Platform:
- Purpose: Bespoke TCR Discovery for optimal targets.
- Key Features: Identifies highly specific and potent TCRs using machine learning and high-throughput screening.
2. TUNE™ Platform:
- Purpose: Engineering T cells for sustained efficacy.
- Key Features: Utilizes synthetic biology tools to enhance persistence and functional durability of TCR-T cell therapies within the tumor microenvironment.
3. THRIVE™ Platform:
- Purpose: Manufacturing optimized cell products.
- Key Features: Combines cell therapy manufacturing and gene editing to enhance T cell fitness and functionality for superior anti-tumor responses.
Bispecific T Cell Engagers:
1. TETHER™ Platform:
- Purpose: Redirecting endogenous T cells with T Cell Engagers.
- Key Features: Utilizes affinity maturation to create bispecific T Cell Engagers, targeting specific oncogenic drivers for sustained anti-tumor activity.
Recent Developments
New Product Launches:
- KRAS G12V Phase 1 Program:
- Details: First patient dosed in the trial, presented at the American Society of Clinical Oncology (ASCO) 2024 Annual Meeting.
New Features Added to Existing Products:
No information is available.
New Partnerships:
- 06.02.2023: Affini-T taps Sanofi alum to lead hunt for partnerships.
Recent Presentations:
- 05.28.2024: KRAS G12V Phase 1 Program presentation at the ASCO 2024 Annual Meeting.
- 05.01.2024: Preclinical data presented targeting KRAS G12D and TP53 R175H at the ASGCT 27th Annual Meeting.
- 04.07.2024: Preclinical data presented for KRAS G12D and p53 R175H at the AACR Annual Meeting 2024.
- 03.13.2024: Preclinical data and trials in progress presentations at the AACR Annual Meeting.
Corporate Presentations
- 05.08.2024: Loss of Heterozygosity is Low for Specific HLA Alleles in Cancer Patients with Driver Mutations.
- 05.08.2024: THRIVE™ Non-Viral Targeted Transgene Knock-In Platform generates potent TCR T Cell products for solid cancers.
- 04.07.2024: Poster presentations at the AACR Annual Meeting 2024.
Contact Information
Headquarters:
100 Forge Road, Watertown, MA 02472, Boston
Legal: Terms & Conditions | Privacy Policy
© 2024 AFFINI-T THERAPEUTICS INC.
